vs
再生元制药（REGN）与Ross Stores（ROST）财务数据对比。点击上方公司名可切换其他公司
Ross Stores的季度营收约是再生元制药的1.6倍（$5.6B vs $3.6B），再生元制药净利率更高（20.2% vs 9.1%，领先11.0%），再生元制药同比增速更快（19.0% vs 10.4%），再生元制药自由现金流更多（$848.3M vs $617.8M），过去两年再生元制药的营收复合增速更高（0.8% vs -3.6%）
再生元制药是一家总部位于美国纽约州韦斯特切斯特县的生物技术企业，成立于1988年。公司最初围绕神经营养因子及其再生能力开展研究，这也是其名称的由来，后续业务逐步拓展至细胞因子与酪氨酸激酶受体领域，首款产品为VEGF陷阱类药物。
Ross Stores, Inc.是美国知名折扣百货连锁集团，旗下核心品牌为Ross Dress for Less，总部位于加利福尼亚州都柏林，是美国规模最大的平价零售商。截至2024年7月，集团在全美43个州、华盛顿特区、波多黎各及关岛共运营1795家门店，暂未覆盖新英格兰地区及阿拉斯加，另拥有门店数超353家的折扣零售品牌DD's Discounts。
REGN vs ROST — 直观对比
营收规模更大
ROST
是对方的1.6倍
$3.6B
营收增速更快
REGN
高出8.6%
10.4%
净利率更高
REGN
高出11.0%
9.1%
自由现金流更多
REGN
多$230.5M
$617.8M
两年增速更快
REGN
近两年复合增速
-3.6%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $3.6B | $5.6B |
| 净利润 | $727.0M | $511.9M |
| 毛利率 | 89.6% | 28.0% |
| 营业利润率 | 17.8% | 11.6% |
| 净利率 | 20.2% | 9.1% |
| 营收同比 | 19.0% | 10.4% |
| 净利润同比 | -10.1% | 4.7% |
| 每股收益（稀释后） | $6.75 | $1.58 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收REGNROST
| Q1 26 | $3.6B | — | ||
| Q4 25 | $3.9B | $5.6B | ||
| Q3 25 | $3.8B | $5.5B | ||
| Q2 25 | $3.7B | $5.0B | ||
| Q1 25 | $3.0B | $5.9B | ||
| Q4 24 | $3.8B | $5.1B | ||
| Q3 24 | $3.7B | $5.3B | ||
| Q2 24 | $3.5B | $4.9B |
净利润REGNROST
| Q1 26 | $727.0M | — | ||
| Q4 25 | $844.6M | $511.9M | ||
| Q3 25 | $1.5B | $508.0M | ||
| Q2 25 | $1.4B | $479.2M | ||
| Q1 25 | $808.7M | $586.8M | ||
| Q4 24 | $917.7M | $488.8M | ||
| Q3 24 | $1.3B | $527.1M | ||
| Q2 24 | $1.4B | $488.0M |
毛利率REGNROST
| Q1 26 | 89.6% | — | ||
| Q4 25 | — | 28.0% | ||
| Q3 25 | — | 27.6% | ||
| Q2 25 | — | 28.2% | ||
| Q1 25 | — | 26.5% | ||
| Q4 24 | — | 28.3% | ||
| Q3 24 | — | 28.3% | ||
| Q2 24 | — | 28.1% |
营业利润率REGNROST
| Q1 26 | 17.8% | — | ||
| Q4 25 | 22.7% | 11.6% | ||
| Q3 25 | 27.3% | 11.5% | ||
| Q2 25 | 29.4% | 12.2% | ||
| Q1 25 | 19.5% | 12.4% | ||
| Q4 24 | 26.1% | 11.9% | ||
| Q3 24 | 31.7% | 12.5% | ||
| Q2 24 | 30.2% | 12.2% |
净利率REGNROST
| Q1 26 | 20.2% | — | ||
| Q4 25 | 21.7% | 9.1% | ||
| Q3 25 | 38.9% | 9.2% | ||
| Q2 25 | 37.9% | 9.6% | ||
| Q1 25 | 26.7% | 9.9% | ||
| Q4 24 | 24.2% | 9.6% | ||
| Q3 24 | 36.0% | 10.0% | ||
| Q2 24 | 40.4% | 10.0% |
每股收益（稀释后）REGNROST
| Q1 26 | $6.75 | — | ||
| Q4 25 | $7.78 | $1.58 | ||
| Q3 25 | $13.62 | $1.56 | ||
| Q2 25 | $12.81 | $1.47 | ||
| Q1 25 | $7.27 | $1.79 | ||
| Q4 24 | $8.12 | $1.48 | ||
| Q3 24 | $11.54 | $1.59 | ||
| Q2 24 | $12.41 | $1.46 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $4.1B |
| 总债务越低越好 | $2.0B | $1.5B |
| 股东权益账面价值 | $31.4B | $5.9B |
| 总资产 | $40.9B | $15.4B |
| 负债/权益比越低杠杆越低 | 0.06× | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资REGNROST
| Q1 26 | — | — | ||
| Q4 25 | $8.6B | $4.1B | ||
| Q3 25 | $8.4B | $3.8B | ||
| Q2 25 | $7.5B | $3.8B | ||
| Q1 25 | $8.3B | $4.7B | ||
| Q4 24 | $9.0B | $4.3B | ||
| Q3 24 | $9.8B | $4.7B | ||
| Q2 24 | $9.8B | $4.7B |
总债务REGNROST
| Q1 26 | $2.0B | — | ||
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.5B |
股东权益REGNROST
| Q1 26 | $31.4B | — | ||
| Q4 25 | $31.3B | $5.9B | ||
| Q3 25 | $31.0B | $5.7B | ||
| Q2 25 | $29.9B | $5.6B | ||
| Q1 25 | $29.4B | $5.5B | ||
| Q4 24 | $29.4B | $5.3B | ||
| Q3 24 | $29.3B | $5.1B | ||
| Q2 24 | $28.2B | $4.9B |
总资产REGNROST
| Q1 26 | $40.9B | — | ||
| Q4 25 | $40.6B | $15.4B | ||
| Q3 25 | $40.2B | $14.5B | ||
| Q2 25 | $38.2B | $14.3B | ||
| Q1 25 | $37.5B | $14.9B | ||
| Q4 24 | $37.8B | $14.9B | ||
| Q3 24 | $37.4B | $14.7B | ||
| Q2 24 | $36.1B | $14.5B |
负债/权益比REGNROST
| Q1 26 | 0.06× | — | ||
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | — | 0.40× | ||
| Q4 24 | — | 0.42× | ||
| Q3 24 | — | 0.48× | ||
| Q2 24 | — | 0.50× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.1B | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $848.3M | $617.8M |
| 自由现金流率自由现金流/营收 | 23.5% | 11.0% |
| 资本支出强度资本支出/营收 | 6.4% | 3.7% |
| 现金转化率经营现金流/净利润 | 1.48× | 1.62× |
| 过去12个月自由现金流最近4个季度 | $4.1B | $2.0B |
8季度趋势，按日历期对齐
经营现金流REGNROST
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.2B | $827.1M | ||
| Q3 25 | $1.6B | $668.4M | ||
| Q2 25 | $1.1B | $409.7M | ||
| Q1 25 | $1.0B | $882.6M | ||
| Q4 24 | $1.3B | $513.4M | ||
| Q3 24 | $1.3B | $592.1M | ||
| Q2 24 | $354.0M | $368.9M |
自由现金流REGNROST
| Q1 26 | $848.3M | — | ||
| Q4 25 | $922.0M | $617.8M | ||
| Q3 25 | $1.4B | $466.6M | ||
| Q2 25 | $925.4M | $202.3M | ||
| Q1 25 | $815.8M | $676.6M | ||
| Q4 24 | $1.1B | $333.0M | ||
| Q3 24 | $1.0B | $394.6M | ||
| Q2 24 | $173.5M | $232.7M |
自由现金流率REGNROST
| Q1 26 | 23.5% | — | ||
| Q4 25 | 23.7% | 11.0% | ||
| Q3 25 | 37.8% | 8.4% | ||
| Q2 25 | 25.2% | 4.1% | ||
| Q1 25 | 26.9% | 11.4% | ||
| Q4 24 | 28.1% | 6.6% | ||
| Q3 24 | 28.2% | 7.5% | ||
| Q2 24 | 4.9% | 4.8% |
资本支出强度REGNROST
| Q1 26 | 6.4% | — | ||
| Q4 25 | 6.4% | 3.7% | ||
| Q3 25 | 5.4% | 3.6% | ||
| Q2 25 | 6.0% | 4.2% | ||
| Q1 25 | 7.6% | 3.5% | ||
| Q4 24 | 5.3% | 3.6% | ||
| Q3 24 | 6.5% | 3.7% | ||
| Q2 24 | 5.1% | 2.8% |
现金转化率REGNROST
| Q1 26 | 1.48× | — | ||
| Q4 25 | 1.39× | 1.62× | ||
| Q3 25 | 1.11× | 1.32× | ||
| Q2 25 | 0.82× | 0.85× | ||
| Q1 25 | 1.29× | 1.50× | ||
| Q4 24 | 1.38× | 1.05× | ||
| Q3 24 | 0.96× | 1.12× | ||
| Q2 24 | 0.25× | 0.76× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
REGN
| Sanofi | $1.6B | 45% |
| Other | $507.0M | 14% |
| EYLEA - U.S | $473.0M | 13% |
| Bayer | $287.0M | 8% |
| Libtayo ® - U.S | $286.0M | 8% |
| Other revenue | $171.0M | 5% |
| Libtayo - ROW* | $152.0M | 4% |
| Praluent - U.S | $67.0M | 2% |
| Evkeeza ® - U.S | $46.0M | 1% |
| Lynozyfic ® - Global | $11.0M | 0% |
ROST
暂无分部数据
